Standard Life Investments LTD Buys 115,163 Shares of Amgen Inc. (AMGN)
Standard Life Investments LTD increased its position in Amgen Inc. (NASDAQ:AMGN) by 6.2% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,975,617 shares of the medical research company’s stock after buying an additional 115,163 shares during the period. Amgen makes up approximately 1.4% of Standard Life Investments LTD’s portfolio, making the stock its 26th largest position. Standard Life Investments LTD owned about 0.26% of Amgen worth $300,640,000 at the end of the most recent quarter.
Several other large investors also recently added to or reduced their stakes in AMGN. Bank of Montreal Can acquired a new stake in Amgen during the second quarter valued at approximately $383,036,000. Wellington Management Group LLP boosted its stake in Amgen by 16.0% in the first quarter. Wellington Management Group LLP now owns 13,544,922 shares of the medical research company’s stock valued at $2,030,789,000 after buying an additional 1,864,688 shares during the period. Nordea Investment Management AB boosted its stake in Amgen by 37.1% in the second quarter. Nordea Investment Management AB now owns 5,719,168 shares of the medical research company’s stock valued at $870,171,000 after buying an additional 1,547,099 shares during the period. NN Investment Partners Holdings N.V. acquired a new stake in Amgen during the first quarter valued at approximately $113,507,000. Finally, UBS Asset Management Americas Inc. boosted its stake in Amgen by 12.4% in the first quarter. UBS Asset Management Americas Inc. now owns 3,712,647 shares of the medical research company’s stock valued at $556,636,000 after buying an additional 409,863 shares during the period. 79.15% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Amgen Inc. (NASDAQ:AMGN) traded up 0.25% during midday trading on Thursday, hitting $164.29. The company had a trading volume of 2,369,996 shares. The company has a market capitalization of $122.95 billion, a PE ratio of 16.81 and a beta of 0.94. The company has a 50-day moving average of $170.01 and a 200-day moving average of $162.16. Amgen Inc. has a 12 month low of $139.02 and a 12 month high of $176.85.
Amgen (NASDAQ:AMGN) last announced its earnings results on Wednesday, July 27th. The medical research company reported $2.84 EPS for the quarter, beating analysts’ consensus estimates of $2.74 by $0.10. Amgen had a return on equity of 29.30% and a net margin of 33.07%. The business earned $5.69 billion during the quarter, compared to analysts’ expectations of $5.58 billion. During the same quarter in the prior year, the firm earned $2.57 earnings per share. The business’s revenue was up 5.9% compared to the same quarter last year. Analysts predict that Amgen Inc. will post $11.35 earnings per share for the current year.
Several equities research analysts recently commented on AMGN shares. Vetr cut Amgen from a “hold” rating to a “sell” rating and set a $166.35 price objective on the stock. in a research report on Monday, August 1st. Goldman Sachs Group Inc. reaffirmed a “buy” rating and set a $204.00 price objective on shares of Amgen in a research report on Thursday, September 8th. Cowen and Company reaffirmed a “buy” rating on shares of Amgen in a research report on Monday, September 19th. Jefferies Group reissued a “buy” rating and issued a $187.00 target price on shares of Amgen in a report on Wednesday, July 13th. Finally, Piper Jaffray Cos. reissued a “buy” rating and issued a $193.00 target price on shares of Amgen in a report on Thursday, July 28th. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating and twelve have given a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $184.94.
In other Amgen news, VP Annette Louise Such sold 3,000 shares of the stock in a transaction that occurred on Tuesday, August 2nd. The stock was sold at an average price of $174.59, for a total transaction of $523,770.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 0.20% of the company’s stock.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. The Company’s business segment is human therapeutics. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as Vectibix (panitumumab), Nplate (romiplostim) and Corlanor (ivabradine).
Receive News & Stock Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related stocks with our FREE daily email newsletter.